Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2023-06-14 00:00:00 ET · period of report 2023-06-12 · accession 0001209191-23-037029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-14 | 2023-06-12 | TRVI | Delfini Lisa | CFO | M - OptEx | $0.51 | +2,291 | 30.2K | +8% | +$1,168 |
| D | 2023-06-14 | 2023-06-12 | TRVI | Delfini Lisa | CFO | S - Sale+OE | $2.64 | -610 | 29.6K | -2% | -$1,610 |
| D | 2023-06-14 | 2023-06-12 | TRVI | Delfini Lisa | CFO | M - OptEx | $0.00 | -2,291 | 73.3K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-12 | M | A | 2,291 | $0.51 | 30,209 | D | — | — | |
| 2 | Common | Common Stock | 2023-06-12 | S | D | 610 | $2.64 | 29,599 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2023-06-12 | M | D | 2,291 | $0.00 | 73,335 | D | $0.51 · — to 2032-02-10 | 2,291 Common Stock | (F3) This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |